Re: Farmas USA
Novavax strong data validates purchase of Isconova, says Ladenburg
Ladenburg views the the strong H7N9 data reported by Novavax as a validation of the company's acquisition of Isconova in 2013. With a new BARDA option and previous commitments, Novavax has access to $100M in funding, the firm noted. Ladenburg maintains its Buy rating and $10 price target on Novavax.